|
MechanismPGI2 receptor agonists [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date20 Sep 1995 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.DE |
First Approval Date01 Jan 1990 |
A South African, multicenter, phase 2, non-blinded, randomized controlled trial to determine if aerosolized surfactant plus continuous positive airway pressure (CPAP) compared to CPAP alone can improve the course of infants with respiratory distress syndrome (RDS) by decreasing their need for intratracheal bolus surfactant in the first 72 hours of age
Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
A Partially Blinded, Randomized, Controlled, Parallel-Group, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact in Preterm Infants at Risk of Worsening Respiratory Distress Syndrome
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
100 Clinical Results associated with Aerogen Pharma Limited
0 Patents (Medical) associated with Aerogen Pharma Limited
100 Deals associated with Aerogen Pharma Limited
100 Translational Medicine associated with Aerogen Pharma Limited